Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 10 IN PLASTIC CONTAINER.
TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
Provides parenteral nutrition with amino acids and dextrose to maintain nitrogen balance and provide caloric support in patients unable to tolerate oral or enteral feeding.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
Intravenous infusion: 1.5 to 2.5 g amino acids/kg body weight per day (equivalent to 35-60 mL/kg per day of TRAVASOL 4.25% IN DEXTROSE 10%) as part of total parenteral nutrition. Infusion rate should not exceed 0.2 g amino acids/kg per hour.
None Documented
None Documented
Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours.
Not applicable as a single entity; amino acids have rapid clearance (minutes to hours), dextrose half-life <15 minutes under normal conditions.
Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible.
Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (90-95%); small amounts excreted in feces (<5%) and bile (<1%). Dextrose is metabolized to CO2 and water.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution